Angle Health raises $600M at a $2.7B valuation for AI-native health benefits

Angle Health, which calls itself the first AI-native healthcare benefits platform for small businesses, announced $600 million in equity financing at a $2.7 billion valuation — a $200 million Series C plus a $400 million tender offer — led by Vitruvian Partners with Town Hall Ventures and existing backers. The company says it serves more than 5,000 employers across 47 states and has posted four straight quarters of profitability.

FINANCE desk — a Y Combinator-rooted, AI-pitched benefits platform just cleared a multi-hundred-million round at a multi-billion valuation while claiming GAAP profitability, a rare combo in health-tech fundraising. Keep the split straight: $200 million is new Series C cash; the $400 million tender is mostly a cash-out for existing holders.

The round was led by Vitruvian Partners, with participation from new investor Town Hall Ventures and existing investors Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator. File the $600 million total, the $200 million Series C / $400 million tender split, the $2.7 billion valuation, the Vitruvian lead, those named participants, and the later-this-month close as Angle Health’s. This desk is not inventing a check-size split beyond that printed $200 million / $400 million cut, an ownership percentage, or a closed trade.

Angle Health describes itself as the first AI-native healthcare benefits platform — an alternative to traditional small-business health plans. It says it serves more than 5,000 employers with customized plans in 47 states, and that employers with as few as two employees can use the platform, with the minimum varying by state. File that first-AI-native / 5,000 / 47-state / two-employee picture as Angle Health’s. “First” is company wording — not a desk ranking. This desk did not count employers or sit with a broker.

Company claims on the same page — attribute, do not independently certify: four consecutive quarters of EBITDA and GAAP net income profitability, about 120% year-over-year growth, and nearly $1 billion in annualized premium-equivalents. EBITDA is earnings before interest, taxes, depreciation, and amortization — a cleaned-up operating-profit figure. GAAP net income is the official U.S. profit number after every expense. Premium-equivalents are a run-rate for the health-plan dollars flowing through the book, not cash already in the bank. File those four-quarter / 120% / nearly-$1-billion lines as Angle Health’s. This desk did not sit on the books or treat those lines as an audited close.

Named voices on the release: Ty Wang, co-founder and CEO of Angle Health, and Jeremy Gelber, partner at Vitruvian. Wang says access to great healthcare should not depend on the size of the company you work for, and that this financing lets Angle reach more small employers. Gelber says Angle replaced archaic systems and manual workflows with a healthcare platform built for the AI era. File the names, titles, and those attributed lines as theirs, via Angle Health. Their other sentences stay in Sources.

Same-day TechCrunch: Julie Bort reports the $200 million Series C plus $400 million tender at a $2.7 billion valuation, the Vitruvian lead, and the same named backers. TechCrunch says Angle is a winter 2020 Y Combinator alum, that the tender lets employees cash out some shares, and that Angle helps small businesses obtain and manage level-funded health plans — plans that sit between fully insured coverage, where the carrier takes the risk, and self-funded coverage, where the employer pays the bills. File the YC / employee-tender / level-funded picture as TechCrunch’s. Extra wire-only color stays in Sources.

Same-day Wall Street Journal, as reprinted by Blumberg Capital: Maria Armental reports Vitruvian is leading a $600 million investment valuing Angle at $2.7 billion, more than doubling a December mark when Portage Ventures led a $134 million investment. The same Journal piece reports the $400 million secondary priced at a $2.5 billion valuation and gave liquidity to early backers. File the December / $134 million / $2.5 billion secondary-price lines as the Journal’s, via that reprint. This desk did not read a closed term sheet.

Plain English for the rest of the card: Series C = a later growth-equity round, cash in after earlier lettered rounds. tender offer / secondary = a buy of existing shares, mostly liquidity for current holders, not all new cash onto the company balance sheet. valuation = what the company is said to be worth in this deal. AI-native benefits platform = Angle’s name for software that prices, builds, and runs small-business health plans with AI in the stack. level-funded = TechCrunch’s term for a plan between fully insured and self-funded. EBITDA = a cleaned-up operating-profit figure. GAAP net income = official U.S. profit after every expense. premium-equivalents = a run-rate for health-plan dollars on the book. YC = Y Combinator, the startup program Angle came through. This is a disclosed company raise, not a stock listing and not investment advice.

PRIMARY here: Angle Health’s 18 Sep 2026 company announcement — Tier A PRIMARY company source, the original record. TechCrunch is same-day independent Tier C corroboration of the $200 million Series C / $400 million tender split, the $2.7 billion mark, the Vitruvian lead, and the YC / level-funded color. The Wall Street Journal via Blumberg Capital’s reprint is same-day independent Tier B corroboration of the $600 million / $2.7 billion mark, the December Portage $134 million backdrop, and the $2.5 billion secondary price. The $600 million total, the $200 million Series C / $400 million tender split, the $2.7 billion valuation, the later-this-month close, the Vitruvian lead, Town Hall Ventures / Blumberg Capital / Portage Ventures / PruVen Capital / Y Combinator, the first-AI-native / 5,000-employer / 47-state / two-employee picture, the four-quarter EBITDA and GAAP profitability / ~120% growth / nearly-$1-billion premium-equivalent claims, and the Wang / Gelber titles and attributed lines are company-attributed. The YC winter-2020 / employee-tender / level-funded picture is TechCrunch-attributed. The December $134 million / more-than-double / $2.5 billion secondary-price lines are Journal-attributed via the reprint. Growth, profitability, and premium-equivalent figures stay company-attributed — not independently audited here. NOT claimed: an audited close, that Angle replaces all insurers, medical outcomes this desk measured, that the tender is all new cash on the balance sheet, that this desk saw a term sheet, a stock tip, or investment advice. Distinct from the already-filed nara-health-14m, tandem-health-100m-series-b, factory-200m-5b-valuation, and crusoe-3-9b-series-f.